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INTRODUCTION
Cancer of an unknown primary site (CUPS) is defined as a bi­
opsy proven metastatic malignant tumor whose primary site 
cannot be identified during the pretreatment evaluation. Early 
dissemination, the unpredictability of the metastatic pattern, 
and aggressiveness constitute the fundamental characteris­
tics of these tumors [1,2]. CUPS have various heterogenous 
clinical and pathologic features, yet within this diverse group 
there are specific clinical and/or pathologic features that can 
be used to define several subsets of patients who have favor­
able prognoses [3]. For these favorable subsets, taxane based 
chemotherapy was very effective for a subset of woman with 
papillary serous peritoneal adenocarcinoma. We describe here 
an unusual case of CUPS that manifested with large multiple 
intraabdominal lymph nodes. We successfully treated the pa­
tient with taxane based chemotherapy and surgery.
CASE REPORT
A 52 year old woman underwent [
18F]­FDG PET/CT for rou­  for rou­
tine health screening. She had suffered from vague abdominal 
dis  comfort. She had no significant past medical history. On PET/
CT, multiple hypermetabolic lymph nodes encasing the inferi­
or ve  na cava and abdominal aorta were detected (SUVmax, 14.9 
in the retrocaval area), and there were no other hypermetabolic 
abnormalities (Fig. 1A). On physical examination, there was mild 
tenderness on the mid­abdomen. The la  bo  ratory examinations 
were within normal ranges including complete blood count, 
renal function tests, and liver function tests. Of the tumor mark­
er tests, only CA­125 was elevated to 250 U/mL. Neck, chest, 
and ab  dominal CT, pelvic MRI, gastroduodenoscopy and colo­
noscopy were performed for further evaluation. The gastro­
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Cancers of an unknown primary site are heterogenous with respect to their clinical and pathologic features. They are generally 
very aggressive, but specific favorable subsets have a better prognosis. For these favorable subsets, taxane based chemotherapy 
is very effective for a subset of woman with papillary serous peritoneal adenocarcinoma. A 52 year­old woman underwent [
18F]­
FDG PET/CT for routine health screening. On PET/CT, multiple hypermetabolic lymph nodes were detected in the paraaortic 
spaces, and there were no other hypermetabolic abnormalities. The patient was diagnosed with an unknown primary cancer 
that probably originated from the ovary or peritoneum, according to clinical studies and biopsy results. This was not a typical 
case of a favorable subset of cancer of an unknown primary site, but the tumor showed complete biologic response to taxane 
based chemotherapy as revealed by PET/CT, and necrotic tumor cells were confirmed by surgery.
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duodenoscopy and colonoscopy were negative. Abdominal 
CT showed about 6 cm sized multiple lymph nodes encasing 
the abdominal aorta (Fig. 2A). There were no abnormalities in 
both ovaries by pelvic MRI. She underwent a laparoscopic sur­
gi  cal biopsy. The results showed metastatic carcinoma and the 
tumor cells were positive for cytokeratin (CK), CK7, estro  gen 
receptor (ER), CA­125 and Wilm’s tumor­1 (WT­1) on immu­
nohistochemical staining (Fig. 3A, B). The other immunohisto­
chemical stains were negative, including gross cystic disease 
fluid protein­15 (GCDFP­15), CK20 and progesterone receptor 
(PR). The patient was diagnosed with cancer of an unknown 
primary site, and it probably originated from the ovary or peri­
toneum on the basis of the clinical studies and biopsy results. 
We thought that the tumor mass could not be completely re­
sected due to encasement of the great vessels, and therefore 
combination chemotherapy that consisted of paclitaxel and 
carboplatin was started. The follow­up CT after 6 cycles of che­
motherapy showed marked partial response according to the 
RECIST criteria, that is, the tumor decreased from 6×5 cm to 
2×2 cm, and so we planned a debulking operation (Fig. 2B). 
Preoperative PET/CT showed no hypermetabolism in the rem­
nant lesion (Fig. 1B). The patient underwent transabdominal 
Fig. 1. (A) The [
18F]FDG PET/CT showed multiple conglo  me  rated hyper-
metabolic lymph nodes encasing the inferior vena cava and abdominal 
aorta in the retrocaval, portocaval and paraaortic spaces. (B) The pre-
opera  tive [
18F]FDG PET/CT revealed that there were no hy  per  metabolic 
lesions in the remnant lymph nodes.
Fig. 2. (A) The initial CT showed huge 
intra  abdominal lym  ph nodes encasing 
the inferior vena cava and abdominal 
aorta. (B) The follow-up CT after 6 cycles 
of taxane based che    mo    therapy showed a 
marked partial res  ponse according to the 
RECIST criteria.
Fig. 3. (A) The laparoscopic biopsy results showed the tumor cells that have pleomorphic nuclei and small cytoplasm (H&E, ×100). (B) The 
immunohistochemical staining results showed the tumor cells were positive for Wilm’s tumor-1. (C) The operative biopsy results showed only 
extensive necrosis in the remnant lymph nodes without tumor cells (H&E, ×10).Necrotic unknown primary cancer revealed by PET
J Gynecol Oncol Vol. 23, No. 1:65-68 www.ejgo.org 67
hysterectomy, both salpingo­oophorectomy and pelvic/para­
aortic lymph nodes dissection. The operative biopsy results 
showed only necrotic cell debris in the lymph nodes without 
tumor cells, and there were no other tumor cells in the female 
genital organs (Fig. 3C). An additional 6 cycles of chemotherapy 
were administered after surgery. She is on follow­up without 
evidence of recurrence.
DISCUSSION
For CUPS, the specific favorable subsets are treatable, and initial 
identification these patients is imperative for their optimal ma­
nage  ment. At least five of these favorable subsets have clinical 
features similar to specific cancer types: 1) women with axillary 
lymph node metastasis, breast cancer; 2) men with blastic bone 
metastasis and tumor staining or elevated serum levels of pro­
state specific antigen, prostate cancer; 3) young men with the 
extragonadal germ cell syndrome, germ cell tumor; 4) isolated 
neck nodes involved with squamous cell carcinoma, head and 
neck primary cancer; 5) woman with papillary serous perito­
neal adenocarcinoma, primary peritoneal carcinoma or ovary 
cancer. Therapy directed at the presumed primary benefits 
these patients, and this supports the idea that at least some 
CUPS retain similar sensitivity to therapies that are known to 
be useful for the known primaries [2]. A woman with papillary 
serous peritoneal adenocarcinoma has clinical features similar 
to those for advanced ovarian cancer including ascites, tumor 
involvement usually limited to the peritoneal surfaces and el­
evated serum levels of CA­125, yet there is no evidence of pri­
mary tumor in the ovaries [4]. These patients should be man­
aged as stage III ovarian cancer with taxane/platinum based 
systemic chemotherapy. The median complete response rate 
is 20%, the median survival is 16 months and the median long 
term survival (>2 years) is 16% [3,5]. 
This was not a typical case of a favorable subset of CUPS. This 
patient manifested with only huge multiple intraabdominal 
lym  ph nodes, yet we chose taxane based chemotherapy accor­
ding to the immunohistochemical results. The main positive 
markers for ovarian adenocarcinoma are ER, CA­125, mesothelin, 
and WT­1, and the diagnosis of primary ovarian tumors is favored 
by the CK7
+/CD20
­ [6]. The immunohistochemical results of 
the tumor cells in this case were CK7
+/CK20
­, ER
+, CA­125
+, and 
WT­1
+. Besides, the tumors showed complete biologic res  pon­
se to taxane based chemotherapy as revealed by PET/CT and 
necrotic tumor cells were confirmed by surgery.
Imaging has a fundamental role in oncology, especially for 
assessing the tumor response to therapy. The current conven­
tional imaging follow­up is based on morphological criteria 
with the changes of the tumor dimensions determining a 
response or tumor progression. PET/CT provides an indication 
of the metabolic and proliferative activity within tumors. It is 
useful in the early evaluation of a tumor response because 
changes in the gross tumor size are notably delayed, and they 
substantially lag behind the biological and molecular changes 
that are known to occur early in responders [7,8]. Monitor­
ing the early treatment response will allow modifying and 
adapting treatment on the basis of the patient’s treatment 
response. Ultimately, the aim is to improve the outcomes 
and reduce the acute and late treatment­related side effects 
to achieve the best possible therapeutic gain and quality of 
life. PET/CT has been recently widely used to evaluate the 
tumor response to chemotherapy for various cancers such as 
esophageal cancer, head and neck cancer, lung cancer, breast 
cancer and lymphoma. It can also be useful for an unknown 
primary cancer. In this case, we performed PET/CT for evaluat­
ing the extent of disease and the treatment response to che­
motherapy before the debulking operation. 
In conclusion, immunohistochemical evaluation of CUPS 
to predict the primary sites is very important for the optimal 
treatment, and PET/CT can also be used for CUPS to evaluate 
the tumor response to chemotherapy.
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Standards for Different Types of Articles
Guidelines for six different types of articles have been adopted by the Journal of Gynecologic Oncology:
1. CONSORT (Consolidated Standards of Reporting Trials) standards for reporting randomized trials
2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta­analyses) guidelines for 
reporting systematic reviews and meta­analyses
3. MOOSE (Meta­analysis of Observational Studies in Epidemiology) guidelines for meta­analyses 
and systematic reviews of observational studies
4. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for 
the reporting of observational studies
5. STARD (Standards for Reporting of Diagnostic Accuracy) standards for reporting studies of diag­
nostic accuracy
6. REMARK (Reporting of Tumor Markers Studies) guidelines for reporting tumor marker prognos­
tic studies
  Investigators who are planning, conducting, or reporting randomized trials, meta­analyses of ran­
domized trials, meta­analyses of observational studies, observational studies, studies of diagnostic 
accuracy, or tumor marker prognostic studies should be familiar with these sets of standards and 
follow these guidelines in articles submitted for publication.
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